Darifenacin: a novel M₃ muscarinic selective receptor antagonist for the treatment of overactive bladder

Bibliography

• ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Ain. J. Obstet. Cynecol. (2002) 187:116–126.
   PubMed Web of Science ®Google Scholar
• STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Ur)]. (2003) 20:327–336.
   PubMed Web of Science ®Google Scholar
• •Findings of a national telephone survey designed to estimate the prevalence and burden of OAB within US adults.
   Google Scholar
• ABRAMS P, KELLEHER CJ, KERR LA, ROGERS RG: Overactive bladder significantly affects quality of life. Am. J. Manag. Care. (2000) 6\(Suppl. 11):S580–S590.
   Google Scholar
• MILSOM I, ABRAMS P, CARD OZO L et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. EIU Int. (2001) 87:760–766.
   Google Scholar
• THOM DH: Overactive bladder: epidemiology and impact on quality of life. Patient Care (2000) Winter (Suppl.):6–14.
   Google Scholar
• •A review of the epidemiology of OAB and its impact on quality of life.
   Google Scholar
• RICCI JA, BAGGISH JS, HUNT TL et al.: Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin. Ther. (2001) 23:1245–1259.
   PubMed Web of Science ®Google Scholar
• HU T-W, WAGNER TH, BENTKOVER JD et al.: Estimated economic costs of overactive bladder in the United States. Urology (2003) 61:1123–1128.
   PubMed Web of Science ®Google Scholar
• ANDERSSON K-E, APPELL R, AWAD S et al.: Pharmacological treatment of urinary incontinence. In: Incontinence, 2nd International Consultation on Incontinence. P Abrams, S Khoury, A Wein, (Eds), Plymbridge Distributors Ltd., Plymouth, UK (2002):480–511.
   Google Scholar
• CHESS-WILLIAMS R, CHAPPLE CR, YAMANISHI T, YASUDA K, SELLERS DJ: The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharmacol (2001) 21:243–248.
   PubMedGoogle Scholar
• FETSCHER C, FLEICHMAN M, SCHMIDT M, KREGE S, MICHEL MC: M3 muscarinic receptors mediate contraction of human urinary bladder. BE J. Pharmacol (2002) 136:641–643.
   PubMed Web of Science ®Google Scholar
• CAULFIELD MP, BIRDSALL NJ: International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev (1998) 50:279–290.
   Google Scholar
• ANDERSSON K-E: Potential benefits of muscarinic M3 receptor selectivity. Eur. Urol. (2002) 1:23–28.
   Web of Science ®Google Scholar
• •Concise review on the potential benefits of muscarinic M3 receptor selectivity in the treatment of OAB.
   Google Scholar
• MIYAMAE K, YOSHIDA M, MURAKAMI S et al: Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology (2003) 69:205–211.
   PubMed Web of Science ®Google Scholar
• NAPIER C, GUPTA P: Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol Urodyn. (2001) 20(4): Abstract A445.
   Google Scholar
• NAPIER C, LASKEY P, GUPTA P et al.: Competitive and reversible interaction of darifenacin with human recombinant M3 receptors. Eur. Urol. (2003) 2(1) Abstract 780.
   Google Scholar
• ALEXANDROU A, CLARINGBOLD A, HARRIS J et al.: Darifenacin has a low affinity for muscarinic M1 receptors in dog saphenous vein confirming its M3 selectivity. Eur. Ur)]. (2003) 2(1):117.
   Google Scholar
• HOWARD TE, McRITCHIE B, SAWYER PJT, WALLIS RM: Effect of darifenacin and other muscarinic antagonists on gastric acid secretion in conscious dogs. BE J. Pharmacol (1998) 123(Suppi.):191P.
   Google Scholar
• CHUA CB, HARRISS DR, MARSH KA, HILL SJ, BATES CP: Effect of darifenacin on muscarinic responses in normal and unstable human detrusor smooth muscle cells. Neurourol Urodyn. (1997) 16:355–356.
   Google Scholar
• WESNES K, LIPTON RB, KOLODNER K, EDGAR C: Darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers. Eur. Urol. (2004) 3(2):131.
   Google Scholar
• NICHOLS D, COLLI E, GOKA J, WESNES K.: Darifenacin demonstrated no adverse effect on cognitive and cardiac function: results from a double-blind, randomised, placebo-controlled study. Neurourol Urodyn. (2001) 20(4) Abstract A354.
   Google Scholar
• CULP DJ, LUO W, RICHARDSON LA, WATSON GE, LATCHNEY LR: Both M1 and M3 receptors regulate exocrine secretion by mucous acini. Am. J. Physiol (1996) 271:C1963–C1972.
   PubMed Web of Science ®Google Scholar
• CHIBA T, BHARUCHA AE, THOMFORDE GM, KOST LJ, PHILLIPS SF: Model of rapid gastrointestinal transit in dogs: effects of muscarinic antagonists and nitric oxide Expert Op/n. Investig. Drugs (2004) 13(11)1499 synthase inhibitor. Neurogastroenterol. Mot. (2002) 14:535–541.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI S, IKEDA K, SUZUKI M, YAMADA T, MIYATA K: Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. fpn. JPharmacol. (2001) 86:281–288.
   Google Scholar
• NEWGREEN DT, ANDERSON CWP, CARTER AJ, NAYLOR AM: Darifenacin — a novel bladder-selective agent for the treatment of urge incontinence. Neurourol. Urodyn. (1995) 14:555–556.
   Google Scholar
• QUINN P, McINTYRE P, MINER WD et al.: hi vivo profile of darifenacin, a selective muscarinic M3 receptor antagonist. Br. J. Pharmacol. (1996) 119 (Suppl.):198P.
   Google Scholar
• BEAUMONT KC, CUSSANS NJ, NICHOLS DJ, SMITH DA: Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and marl. Xenobiotica (1998) 28:63–75.
   PubMed Web of Science ®Google Scholar
• •Report on the pharmacokinetics and metabolism of darifenacin in humans and other species.
   Google Scholar
• KERBUSCH T, WAHLBY U, MILLEGAN PA, KARLSSON MO: Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, including saturable first pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br..! Pharmacol. (2003) 56:639–652.
   Web of Science ®Google Scholar
• CHAPPLE C, KELLEHER K, PERRAULT L: Darifenacin, an M3 selective receptor antagonist, improves quality of life in patients with overactive bladder. Progr. Urol. (2004) 14\(Suppl. 3):22.
   Google Scholar
• SALVATORE S: Darifenacin does not affect the pharmacokinetics of a combined oral contraceptive (Microgynonn in healthy women. Int. Urogynecol. 1 (2001) 12 (Suppl. 3):532.
   Google Scholar
• NICHOLS DJ: No effect of food on pharmacokinetics of darifenacin in multiple doses. Pharmacol. Toxicol. (2001) 89\(Suppl. 1):89.
   Google Scholar
• CHAPPLE C: Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of Phase III studies. J. Urol. (2004) 171\(Suppl. 4):130.
   Google Scholar
• HAAB F, STEWART L, DWYER P: Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. (2004) 45:420–429.
   PubMed Web of Science ®Google Scholar
• FOOTE JE: Darifenacin a highly M3 selective muscarinic receptor antagonist is effective and well tolerated by elderly patients with overactive bladder. J. Am. Geriatr. Soc. (2004) 52(4 Suppl.):5126.
   Google Scholar
• KHULLAR V: Darifenacin, an M3 selective receptor antagonist, reduces the frequency of nocturnal awakening, an important symptom of overactive bladder. J. Urol. (2004) 171(4 Suppl.):131.
   Google Scholar
• CARDOZO L, PRESCOTT K, SERDAREVIC D et al: Can medication prolong warning time in overactive bladder? Neurourol. Urodyn. (2003) 22(5) Abstract A74.
   Google Scholar